氟卡尼在儿茶酚胺能多形性室性心动过速治疗中的作用
The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
作者信息
Lieve Krystien Vv, Wilde Arthur A, van der Werf Christian
机构信息
Heart Centre, Academic Medical Centre, Amsterdam, The Netherlands.
Heart Centre, Academic Medical Centre, Amsterdam, The Netherlands; Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Jeddah, Kingdom of Saudi Arabia.
出版信息
Arrhythm Electrophysiol Rev. 2016 May;5(1):45-9. doi: 10.15420/aer.2016.3.3.
Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of structural heart disease. The cornerstone of medical therapy for CPVT is β-blockers. However, recently flecainide has been added to the therapeutic arsenal for CPVT. In this review we summarise current data on the efficacy and role of flecainide in the treatment of CPVT.
摘要
儿茶酚胺能性多形性室性心动过速（CPVT）是一种罕见但严重的遗传性心律失常疾病，其症状包括晕厥以及在无结构性心脏病的情况下，通常由运动或情绪诱发的多形性室性心动过速或心室颤动导致的心源性猝死。CPVT药物治疗的基石是β受体阻滞剂。然而，最近氟卡尼已被纳入CPVT的治疗手段。在本综述中，我们总结了目前关于氟卡尼治疗CPVT的疗效和作用的数据。
相似文献
1
The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.氟卡尼在儿茶酚胺能多形性室性心动过速治疗中的作用
Arrhythm Electrophysiol Rev. 2016 May;5(1):45-9. doi: 10.15420/aer.2016.3.3.
2
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.氟卡尼治疗可抑制 CASQ2 相关儿茶酚胺敏感性多形性室性心动过速患者运动诱发的室性心律失常。
Heart Rhythm. 2013 Nov;10(11):1671-5. doi: 10.1016/j.hrthm.2013.08.011. Epub 2013 Aug 13.
3
The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia.氟卡尼在儿茶酚胺能多形性室性心动过速中的抗心律失常机制
Front Physiol. 2022 Mar 9;13:850117. doi: 10.3389/fphys.2022.850117. eCollection 2022.
4
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.氟卡尼成功治疗儿茶酚胺多形性室性心动过速 1 例报告并文献复习
Europace. 2011 Jun;13(6):897-901. doi: 10.1093/europace/euq517. Epub 2011 Feb 2.
5
High-dose flecainide with low-dose β-blocker therapy in catecholaminergic polymorphic ventricular tachycardia: A case report and review of the literature.高剂量氟卡尼联合低剂量β受体阻滞剂治疗儿茶酚胺能多形性室性心动过速：一例报告并文献复习
J Cardiol Cases. 2014 Sep 26;11(1):10-13. doi: 10.1016/j.jccase.2014.08.009. eCollection 2015 Jan.
6
Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.氟卡尼可减少携带兰尼碱受体2（RyR2）基因阳性的儿茶酚胺能多形性室性心动过速患者的室性心律失常。
Rev Esp Cardiol (Engl Ed). 2018 Mar;71(3):185-191. doi: 10.1016/j.rec.2017.04.032. Epub 2017 Aug 5.
7
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.氟卡尼治疗儿茶酚胺敏感性多形性室性心动过速的疗效：一项随机临床试验。
JAMA Cardiol. 2017 Jul 1;2(7):759-766. doi: 10.1001/jamacardio.2017.1320.
8
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.氟卡尼对儿茶酚胺多形性室性心动过速基因型阴性患者运动诱发室性心律失常和复发的影响。
Heart Rhythm. 2013 Apr;10(4):542-7. doi: 10.1016/j.hrthm.2012.12.035. Epub 2012 Dec 31.
9
Catecholaminergic Polymorphic Ventricular Tachycardia.儿茶酚胺能多形性室性心动过速
Arrhythm Electrophysiol Rev. 2022 Apr;11:e20. doi: 10.15420/aer.2022.09.
10
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.氟卡尼治疗可减少儿茶酚胺多形性室性心动过速患者运动诱发的室性心律失常。
J Am Coll Cardiol. 2011 May 31;57(22):2244-54. doi: 10.1016/j.jacc.2011.01.026.
引用本文的文献
1
Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study.儿茶酚胺能多形性室性心动过速患者的长期临床病程：一项超过10年的随访队列研究。
Ann Pediatr Cardiol. 2024 May-Jun;17(3):196-203. doi: 10.4103/apc.apc_101_24. Epub 2024 Oct 1.
2
Explaining the Unexplained: A Practical Approach to Investigating the Cardiac Arrest Survivor.解释无法解释之事：调查心脏骤停幸存者的实用方法
Arrhythm Electrophysiol Rev. 2023 Nov 23;12:e27. doi: 10.15420/aer.2023.06. eCollection 2023.
3
Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia.中国儿科儿茶酚胺多形性室性心动过速患者的临床和遗传特征。
Orphanet J Rare Dis. 2023 Dec 5;18(1):380. doi: 10.1186/s13023-023-02991-0.
4
Catecholaminergic Polymorphic Ventricular Tachycardia.儿茶酚胺能多形性室性心动过速
Arrhythm Electrophysiol Rev. 2022 Apr;11:e20. doi: 10.15420/aer.2022.09.
5
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy.解析 DSC2 致心律失常性心肌病电不稳定性：从离子通道到心电图和针对性药物治疗。
Clin Transl Med. 2021 Mar;11(3):e319. doi: 10.1002/ctm2.319.
6
Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis.氟卡尼治疗儿茶酚胺能多形性室性心动过速患者的安全性和有效性：一项系统评价和荟萃分析。
Medicine (Baltimore). 2019 Aug;98(34):e16961. doi: 10.1097/MD.0000000000016961.
7
For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death.《钟声为谁而鸣：完善心源性猝死风险评估》。
Curr Cardiol Rep. 2019 Aug 2;21(9):106. doi: 10.1007/s11886-019-1191-z.
8
Ion Channel Disorders and Sudden Cardiac Death.离子通道病与心原性猝死
Int J Mol Sci. 2018 Feb 28;19(3):692. doi: 10.3390/ijms19030692.
9
Magnetocardiographic evaluation of nonarrhythmogenic flecainide-induced electrocardiographic T-wave inversion.非致心律失常性氟卡尼诱发心电图T波倒置的磁心动图评估
Anatol J Cardiol. 2017 Apr;17(4):337-339. doi: 10.14744/AnatolJCardiol.2017.7556.
10
Advancements in the use of gene therapy for cardiac arrhythmia.基因治疗在心律失常治疗中的进展。
Heart Rhythm. 2017 Jul;14(7):1061-1062. doi: 10.1016/j.hrthm.2017.03.041. Epub 2017 Apr 4.
本文引用的文献
1
Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.纳多洛尔比β1 选择性β受体阻滞剂在儿茶酚胺多形性室性心动过速患者运动压力测试中降低室性心律失常的发生率和严重程度。
Heart Rhythm. 2016 Feb;13(2):433-40. doi: 10.1016/j.hrthm.2015.09.029. Epub 2015 Sep 30.
2
Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.对于某些对β受体阻滞剂不耐受的儿茶酚胺能多形性室性心动过速患者，氟卡尼单药治疗是一种选择。
Heart Rhythm. 2016 Feb;13(2):609-13. doi: 10.1016/j.hrthm.2015.09.027. Epub 2015 Sep 28.
3
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).2015年欧洲心脏病学会（ESC）室性心律失常患者管理和心脏性猝死预防指南：欧洲心脏病学会（ESC）室性心律失常患者管理和心脏性猝死预防特别工作组。认可机构：欧洲儿科和先天性心脏病协会（AEPC）。
Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29.
4
Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.儿茶酚胺多形性室性心动过速的临床处理：左侧心脏交感神经切除术的作用。
Circulation. 2015 Jun 23;131(25):2185-93. doi: 10.1161/CIRCULATIONAHA.115.015731. Epub 2015 May 27.
5
The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.氟卡尼对人心脏兰尼碱受体的直接作用：关于局部麻醉药在儿茶酚胺相关多形性室性心动过速中作用机制的争论仍在继续。
Circ Res. 2015 Apr 10;116(8):1284-6. doi: 10.1161/CIRCRESAHA.115.306298.
6
Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.儿童儿茶酚胺能多形性室性心动过速：来自一项国际多中心注册研究的治疗策略与结果分析
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):633-42. doi: 10.1161/CIRCEP.114.002217. Epub 2015 Feb 24.
7
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.氟卡尼在 CPVT 中的作用机制不涉及对 RyR2 的直接作用。
Circ Res. 2015 Apr 10;116(8):1324-35. doi: 10.1161/CIRCRESAHA.116.305347. Epub 2015 Feb 3.
8
Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.氟卡尼用于因新型兰尼碱受体2（RYR2）突变导致的侵袭性儿茶酚胺能多形性室性心动过速患者。
Minerva Cardioangiol. 2014 Aug;62(4):363-6.
9
Novel calmodulin mutations associated with congenital arrhythmia susceptibility.与先天性心律失常易感性相关的新型钙调蛋白突变。
Circ Cardiovasc Genet. 2014 Aug;7(4):466-74. doi: 10.1161/CIRCGENETICS.113.000459. Epub 2014 Jun 10.
10
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.一种与儿茶酚胺能多形性室性心动过速相关的新发心脏兰尼碱受体突变（Ser4155Tyr）
Ann Noninvasive Electrocardiol. 2013 Nov;18(6):571-6. doi: 10.1111/anec.12089. Epub 2013 Oct 23.
Zotero 插件